Nyrada Inc (ASX:NYR) is a new US registered, Australia domiciled pharmaceutical company. Our business is drug discovery and drug development in areas of significant community need in the cardiovascular and neurology fields. Our clinical targets are diseases and conditions affecting large numbers of individuals, where current treatment options are suboptimal, and in some cases, non-existent. The guiding principles driving our commercial strategies are: • Sound scientific rationale • Significant unmet clinical need • Large market opportunity • Low number of competitors • Strong IP protection • Favourable regulatory pathway to approval Nyrada’s two main programmes are a cholesterol-lowering drug and a drug to treat brain injury, specifically stroke and traumatic brain injury (TBI).
View Top Employees from Nyrada Inc. (ASX:NYR)| Website | http://www.nyrada.com |
| Revenue | $6 million |
| Employees | 13 (4 on RocketReach) |
| Founded | 2018 |
| Address | 828 Pacific Hwy, Gordon, New South Wales 2072, AU |
| Phone | +61 2 9053 1990 |
| Industry | Pharmaceutical Manufacturing, Drug Manufacturing & Research, Pharmaceuticals, Healthcare |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 541 Companies |
Looking for a particular Nyrada Inc. (ASX:NYR) employee's phone or email?
Nyrada Inc. (ASX:NYR) Questions
The Nyrada Inc. (ASX:NYR) annual revenue was $6 million in 2024.
James Bonnar is the CEO of Nyrada Inc. (ASX:NYR).
4 people are employed at Nyrada Inc. (ASX:NYR).
Nyrada Inc. (ASX:NYR) is based in Gordon, New South Wales.
The NAICS codes for Nyrada Inc. (ASX:NYR) are [54, 325, 32541, 3254, 32, 541].
The SIC codes for Nyrada Inc. (ASX:NYR) are [28, 283].
Top Nyrada Inc. (ASX:NYR) Employees
-
33
-
2
-
1
Related Companies
